Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry

Background— Several biological pathways are activated concomitantly during left ventricular (LV) remodeling. However, the relative contribution of circulating biomarkers representing these distinct pathways to LV geometry is unclear. Methods and Results— We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination. LV geometry was defined on the basis of sex-specific distributions of LV mass (LVM) and relative wall thickness (RWT): normal (LVM and RWT <80th percentile), concentric remodeling (LVM <80th percentile but RWT ≥80th percentile), eccentric hypertrophy (LVM ≥80th percentile but RWT <80th percentile), and concentric hypertrophy (LVM and RWT ≥80th percentile). We related the biomarker panel to LV geometry using polytomous logistic regression adjusting for clinical covariates and used backwards elimination to identify a parsimonious set of biomarkers associated with LV geometry. Modeled individually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related to LV geometry (P<0.01). In multivariable analyses, the biomarker panel was significantly related to altered LV geometry (P<0.0001). On backwards elimination, logARR alone was significantly and positively associated with eccentric (odds ratio per SD increment, 1.20; 95% confidence interval, 1.05 to 1.37) and concentric LV hypertrophy (odds ratio per SD increment, 1.29; 95% confidence interval, 1.06 to 1.58). Conclusions— Our cross-sectional observations on a large community-based sample identified ARR as a key correlate of concentric and eccentric LV hypertrophy, consistent with a major role for the renin-angiotensin-aldosterone system in LV remodeling.

[1]  T. Cappola.  Molecular remodeling in human heart failure. , 2008, Journal of the American College of Cardiology.

[2]  J. Danesh,et al.  Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. , 2007, American journal of epidemiology.

[3]  D. Levy,et al.  Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study , 2007, Circulation.

[4]  A. Yamashina,et al.  Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[5]  F. Neumann,et al.  Regression of Left Ventricular Hypertrophy following Stenting of Renal Artery Stenosis , 2007, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[6]  D. Levy,et al.  Clinical and Genetic Correlates of Aldosterone-to-Renin Ratio and Relations to Blood Pressure in a Community Sample , 2007, Hypertension.

[7]  Nader Rifai,et al.  Multiple Biomarkers and the Risk of Incident Hypertension , 2007, Hypertension.

[8]  Marc A Pfeffer,et al.  Controversies in ventricular remodelling , 2006, The Lancet.

[9]  D. Conen,et al.  Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. , 2006, The American journal of cardiology.

[10]  J. Pratt.  Too much aldosterone--more common than we ever realized? , 2006, American journal of hypertension.

[11]  M. Kubo,et al.  Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. , 2005, Diabetes care.

[12]  J. Jansson,et al.  Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years. , 2005, Thrombosis research.

[13]  A. Temizhan,et al.  The influence of aldosterone on the development of left ventricular geometry and hypertrophy in patients with essential hypertension. , 2004, Japanese heart journal.

[14]  L. Niskanen,et al.  C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men , 2004, Diabetologia.

[15]  D. Levy,et al.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons. , 2004, The New England journal of medicine.

[16]  J. Murabito,et al.  Relations of Serum Aldosterone to Cardiac Structure: Gender-Related Differences in the Framingham Heart Study , 2004, Hypertension.

[17]  D. Levy,et al.  Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. , 2004, European heart journal.

[18]  B. Pitt.  “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy , 1995, Cardiovascular Drugs and Therapy.

[19]  C. Bloor,et al.  Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy , 1997, Molecular and Cellular Biochemistry.

[20]  P. Ridker,et al.  C-reactive protein and the risk of developing hypertension. , 2003, JAMA.

[21]  N. Reichek,et al.  Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential , 2003 .

[22]  M. Nieminen,et al.  Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. , 2002, American heart journal.

[23]  G. Berglund,et al.  Blood Pressure Increase and Incidence of Hypertension in Relation to Inflammation-Sensitive Plasma Proteins , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[24]  T. Horio,et al.  Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[25]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[26]  R. Tracy,et al.  Longitudinal Stability of Coagulation, Fibrinolysis, and Inflammation Factors in Stored Plasma Samples , 2001, Thrombosis and Haemostasis.

[27]  B. Howard,et al.  Fibrinogen and Preclinical Echocardiographic Target Organ Damage: The Strong Heart Study , 2001, Hypertension.

[28]  B. Woodhams,et al.  Stability of coagulation proteins in frozen plasma , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  H. S. Klopfenstein,et al.  M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). , 2001, The American journal of cardiology.

[30]  T. Saruta,et al.  Aldosterone Escape during Angiotensinconverting Enzyme Inhibitor Therapy in Essential Hypertensive Patients with Left Ventricular Hypertrophy , 2001, The Journal of international medical research.

[31]  C. Brilla.  Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection , 2000, Heart.

[32]  N. Lawson,et al.  Aldosterone and renin measurements , 2000, Annals of clinical biochemistry.

[33]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[34]  D. Levy,et al.  Association of blood pressure with fibrinolytic potential in the Framingham offspring population. , 2000, Circulation.

[35]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[36]  B. Pitt,et al.  Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system. , 1998, Circulation.

[37]  H. Schunkert,et al.  Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. , 1998, American heart journal.

[38]  T. Yoshimoto,et al.  Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. , 1997, Hypertension research : official journal of the Japanese Society of Hypertension.

[39]  H. Hense,et al.  Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. , 1997, Heart.

[40]  D. Levy,et al.  Prognosis of left ventricular geometric patterns in the Framingham Heart Study. , 1995, Journal of the American College of Cardiology.

[41]  H. Matsuoka,et al.  Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension , 1995, Journal of hypertension.

[42]  D. Levy,et al.  Impact of Left Ventricular Structure on the Incidence of Hypertension: The Framingham Heart Study , 1994, Circulation.

[43]  D. Levy,et al.  Sex differences in cardiac adaptation to isolated systolic hypertension. , 1993, The American journal of cardiology.

[44]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[45]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[46]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[47]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[48]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.